Ziltivekimab

DB18836InvestigationalProtein Based Therapies

Ziltivekimab is under investigation in clinical trial NCT06200207 (A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation).

Mechanism: Pharmacologically active on Interleukin-6
Curator reviewed
Also known as: Immunoglobulin g1 (255-tyrosine,257-threonine,259-glutamic acid), anti-(human interleukin 6) (human monoclonal 2e2.3a9.6a3 .gamma.1-chain), disulfide with human monoclonal 2e2.3a9.6a3 .kappa.-chain, dimer
Code names: COR-001 · MEDI-5117 · WBP-216

Resolves to

Compound

UNIIAN3Y2B4SX4CAS2226654-05-1

Targets

P05231IL6

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ziltivekimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account